OptimizeRx Corp. (NASDAQ:OPRX) Receives $21.00 Average Price Target from Brokerages

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have earned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $21.00.

OPRX has been the topic of several recent analyst reports. Wall Street Zen raised shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday, December 22nd. Stephens decreased their price target on shares of OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating for the company in a research note on Monday, November 17th. Citizens Jmp boosted their price target on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Finally, Zacks Research downgraded OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC raised its holdings in shares of OptimizeRx by 600.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after purchasing an additional 1,818 shares in the last quarter. Quantbot Technologies LP purchased a new position in OptimizeRx during the second quarter valued at approximately $44,000. BNP Paribas Financial Markets raised its stake in OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after buying an additional 2,215 shares in the last quarter. State of Alaska Department of Revenue bought a new position in OptimizeRx in the fourth quarter worth approximately $62,000. Finally, USA Financial Formulas purchased a new stake in OptimizeRx during the third quarter worth $131,000. 76.47% of the stock is currently owned by institutional investors.

OptimizeRx Stock Down 8.3%

Shares of NASDAQ:OPRX opened at $9.23 on Friday. The firm has a market capitalization of $172.06 million, a PE ratio of 25.88 and a beta of 1.18. The business has a 50 day simple moving average of $12.40 and a two-hundred day simple moving average of $15.53. OptimizeRx has a 1 year low of $3.99 and a 1 year high of $22.25. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.05 and a quick ratio of 3.05.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.